ROME — One-year results of the phase 2 ALTITUDE trial showed efficacy and safety of a one-time in-office injection of ABBV-RGX-314 for the treatment of diabetic retinopathy.
“This investigational drug is an AAV8 vector with anti-VEGF Fab similar to ranibizumab,” Lejla Vajzovic, MD, said at the FLORetina-ICOOR meeting.
Injected into the suprachoroidal space, ABBV-RGX-314 reduces leaky blood vessel formation by giving ocular cells the ability to produce an anti-VEGF Fab.
ALTITUDE is a dose-escalating trial including patients with moderately severe and severe nonproliferative